Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Generate Biomedicines has completed its IPO, raising an impressive $400 million that makes it the largest listing for a biotech on the Nasdaq so far this year. Incubated by investment group Flagship ...

(Bloomberg) --Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Some call it magic -- the ability to make objects appear suddenly out of nowhere. You can create this kind of magic on your website using a few lines of JavaScript ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC ...

England, South Africa and New Zealand are through to the semi-finals of the T20 World Cup, with one more place in the knockout stage still up for grabs. India and West Indies are the sides in ...

New plans are underway to transform the community surrounding the Ravenswood Generating Station in Long Island City, Queens. It comes alongside efforts to turn the natural gas power plant into a ...